StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research report released on Monday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
Shares of NASDAQ:EVOK opened at $4.77 on Monday. The stock has a market capitalization of $7.09 million, a PE ratio of -0.43 and a beta of 0.16. The company’s 50-day moving average price is $4.90 and its two-hundred day moving average price is $5.22. Evoke Pharma has a one year low of $3.54 and a one year high of $13.80.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma at the end of the most recent reporting period.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Further Reading
- Five stocks we like better than Evoke Pharma
- Trading Stocks: RSI and Why it’s Useful
- 3 Must-Hold Stocks with Double-Digit Upside for 2025
- How to Calculate Inflation Rate
- Micron: Why Now Is the Time to Be Brave
- 3 Warren Buffett Stocks to Buy Now
- 3 Stocks That Wall Street Insiders Can’t Stop Buying
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
